President Trump’s nomination of Kevin Warsh to chair the Federal Reserve has injected clarity into the monetary policy outlook for 2026. Market participants now forecast two rate cuts next year, a shift that could reduce Healthpeak Properties’ borrowing costs by an estimated 25–50 basis points. Lower funding expenses would support the company’s 7% dividend yield and enhance its capacity to refinance maturing debt without diluting shareholders. Investors view this development as a tailwind for Healthpeak’s net operating income, particularly in its office and life sciences portfolios, which collectively represent over 60% of the enterprise value.

In the fourth quarter of 2025, Healthpeak reported funds from operations of $0.47 per share, surpassing the consensus estimate of $0.46 and marking a 2.2% increase year‐over‐year. Same‐store net operating income rose by 3.1%, driven by rent escalations in the medical office segment and higher occupancy in the senior housing business. Total quarterly revenue climbed 4.5% versus the prior year, with the life sciences portfolio delivering mid‐single‐digit leasing growth in core markets such as San Diego and Boston. The company reaffirmed its full‐year FFO guidance range of $1.88 to $1.92 per share.

Despite attractive cash flow metrics, a leading research firm downgraded Healthpeak to HOLD, citing poor capital allocation and execution risk associated with its spinoff of senior housing assets into the newly formed Janus Living platform. The report noted that dual external management arrangements and a dual‐CEO structure could delay integration benefits and increase overhead by up to $10 million annually. Healthpeak’s shares trade at a 15–20% discount to net asset value, and the company has underperformed the broad REIT index by nearly 60% since 2019, reflecting investor skepticism about its strategic pivots.

Management outlined a series of portfolio reshaping actions designed to concentrate capital in high‐growth sectors. In Q4, the company completed the disposition of $450 million of noncore office assets, reallocating proceeds to ground‐up life sciences developments expected to deliver stabilized yields of 7.5%–8.0%. Healthpeak also announced a partnership to develop a 200,000 square‐foot research campus in San Francisco, targeting pre‐leasing commitments from three anchor tenants. These initiatives aim to lift total shareholder return by improving portfolio yield by 50–75 basis points over the next two years.